BNC210

BNC210 (also known as IW-4123 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α₇-nicotinic acetylcholine receptor, by Bionomics Limited. It demonstrates clinically significant anxiety reduction in both animal models and in Phase I trials.

It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.

Phase I trials have shown no serious side effects.

Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States, but in November 2014, was released back to Bionomics in a mutual agreement. Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.

As of April 2015, BNC210 is in phase II clinical trials.